Genovese Burford & Brothers Wealth & Retirement Plan Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-65	Closed	-$11K	–	366
2018 Q2	$11K	Hold	65	–	–	﹤0.01%	313
2018 Q1	$11K	Hold	65	–	–	﹤0.01%	317
2017 Q4	$11K	Sell	65 -430	-87%	-$63.7K	0.03%	180
2017 Q3	$75K	Hold	495	–	–	0.03%	118
2017 Q2	$63K	Hold	495	–	–	0.03%	128
2017 Q1	$55K	Hold	495	–	–	0.02%	142
2016 Q4	$37K	Sell	495 -285	-37%	-$23.2K	0.01%	191
2016 Q3	$68K	Sell	780 -350	-31%	-$33.1K	0.03%	132
2016 Q2	$97K	Hold	1,130	–	–	0.04%	102
2016 Q1	$89K	Hold	1,130	–	–	0.04%	94
2015 Q4	$142K	Buy	+1,130	New	+$136K	0.07%	69

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Genovese Burford & Brothers Wealth & Retirement Plan Management's VRTX Position: Q3 2018 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 65 shares — an estimated $11K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in VRTX in Q4 2015 and held it in 11 quarters. The position peaked at $142K in Q4 2015. 697 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Genovese Burford & Brothers Wealth & Retirement Plan Management sold 65 Vertex Pharmaceuticals shares in Q3 2018, an estimated $11K.
Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 11 quarters.
Genovese Burford & Brothers Wealth & Retirement Plan Management's Vertex Pharmaceuticals position peaked at $142K in Q4 2015.
697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q3 2018, filed 13 Nov 2018.